TimeTopicFaculty SpeakerModerator
08:00 – 08:30Registration
08:30 – 08:35Welcome RemarksDr. Koichi Akashi
08:35 – 08:40Opening RemarksDr. Norio Komatsu
Basic Science of MPN
08:40 – 09:15Mutations in MPN: Hereditary Predispositions, Disease Initiators and Drivers of ProgressionDr. Robert Kralovics

Dr. Norio Komatsu  

Dr. Robert Kralovics 

09:15 – 09:40The Role of Wild and Mutant Calreticulin in HematopoiesisDr. Kazuya Shimoda
09:40 – 10:05Molecular Mechanisms Leading to the Development of Myeloproliferative Neoplasms by Mutant CalreticulinDr. Marito Araki
10:05 – 10:25The role of HMGA2 in MPNDr. Chih-Cheng Chen 
MPN Pathology
10:25 – 11:05New WHO Classification of Myeloproliferative NeoplasmsDr. Hans-Michael KvasnickaDr. Masafumi Ito
11:05 – 12:00Lunch
Hot Topic of MPN
12:00 – 12:35MPN Disease Burden: Lessons Learned from PatientsDr. Ruben MesaDr. Yuzuru Kanakura
Asian MPN Session
12:35 – 12:55Childhood Myeloproliferative NeoplasmsDr. Jong Jin Seo

Dr. Keita Kirito

Dr. Dong-Tsamn Lin

12:55 – 13:15Clinical Outcomes of Patients with Primary Myelofibrosis in Japan: A Report of a Nationwide Survey from 1999 to 2015Dr. Katsuto Takenaka
13:15 – 13:35Primary Myelofibrosis in TaiwanDr. Lee-Yung Shih
13:35 – 13:55Chronic Neutrophilic Leukemia: Experience from ChinaDr. Qian Jiang
13:55 – 14:15Coffee Break
IFN Renaissance
14:15 – 14:40IFN Treatment for PVDr. Richard Silver

Dr. Jean-Jacques Kiladjian

Dr. Srdan Verstovsek 

14:40 – 15:00Long Term Results of Peg-IFN Therapy in PV and ETDr. Srdan Verstovsek
15:00– 15:20Results of the PROUD-PV StudyDr. Heinz Gisslinger
15:20 – 15:40Molecular Landscape of MPN: Influence on Response to Therapy and Evolution Under Treatment with Interferon AlphaDr. Bruno Cassinat
15:40 – 16:00Can We Alter MPN Evolution with IFN Therapy?Dr. Jean-Jacques Kiladjian
16:00 – 16:20New Antiviral Mechanism of Interferon on Hepatitis B virusDr. Pei-Jer Chen 
Panel Discussion
16:20 – 16:45Chair: Dr. Jean-Jacques Kiladjian & Dr. Srdan Verstovsek 
16:45 – 16:50Closing RemarksDr. Kazuya Shimoda